Literature DB >> 10583035

Attitudinal survey of voluntary reporting of adverse drug reactions.

I A Eland1, K J Belton, A C van Grootheest, A P Meiners, M D Rawlins, B H Stricker.   

Abstract

AIMS: Voluntary adverse drug reaction (ADR) reporting schemes have operated since the early sixties in many Western countries. It is generally recognized, however, that only a small proportion of ADRs is actually reported. The current survey was conducted to assess attitudes towards reporting of ADRs, and to study which types of ADRs are reported.
METHODS: A questionnaire seeking reasons for nonreporting was sent to a random sample of 10% of medical practitioners in The Netherlands in October 1997. After 6 weeks, a reminder was sent to those who had not responded.
RESULTS: One thousand four hundred and forty-two (73%) questionnaires were returned, of which 94% were complete. The percentage of GPs (51%) which had ever reported an ADR to the national reporting centre was significantly higher than the percentage of specialists (35%), who reported more often to the pharmaceutical industry (34% vs 48%). 86% of GPs, 72% of surgical specialists and 81% of medical specialists had ever diagnosed an ADR, which they had not reported. Uncertainty as to whether the reaction was caused by a drug (72%), the ADR being trivial (75%) or too well known (93%) were the most important reasons for not reporting. 18% were not aware of the need to report ADRs, 22% did not know how to report ADRs, 38% did not have enough time, 36% thought that reporting was too bureaucratic and only 26% of Dutch physicians knew which ADRs to report. A serious ADR, an unlabelled ADR, an ADR to a new drug, history of reporting of one or more ADRs, and specialty were all independently associated with reporting of 16 hypothetical ADRs. Surgical and medical specialists tended to report less often than GPs.
CONCLUSIONS: There is a considerable degree of underreporting, which might partly be explained by lack of knowledge and misconceptions about spontaneous reporting of adverse drug reactions.

Entities:  

Mesh:

Year:  1999        PMID: 10583035      PMCID: PMC2014371          DOI: 10.1046/j.1365-2125.1999.00060.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  [Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands].

Authors:  M M van Riemsdijk; R M Herings; M D Rawlins; B H Stricker
Journal:  Ned Tijdschr Geneeskd       Date:  1995-11-11

2.  Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group.

Authors:  K J Belton
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Physician knowledge, attitudes, and behavior related to reporting adverse drug events.

Authors:  A S Rogers; E Israel; C R Smith; D Levine; A M McBean; C Valente; G Faich
Journal:  Arch Intern Med       Date:  1988-07

4.  Glafenine-associated anaphylaxis as a cause of hospital admission in The Netherlands.

Authors:  B H Stricker; R R de Groot; J H Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom.

Authors:  K J Belton; S C Lewis; S Payne; M D Rawlins; S M Wood
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

6.  A population based case-cohort study of drug-induced anaphylaxis.

Authors:  M M van der Klauw; B H Stricker; R M Herings; W S Cost; H A Valkenburg; J H Wilson
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

  6 in total
  84 in total

1.  Identifying and reducing complications of outpatient medications.

Authors:  B G Petty
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

2.  Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting.

Authors:  C F Green; D R Mottram; P H Rowe; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

3.  Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals.

Authors:  V Bongard; S Ménard-Taché; H Bagheri; K Kabiri; M Lapeyre-Mestre; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

4.  Semi-intensive versus intensive monitoring of adverse drug reactions in a hospital.

Authors:  Slobodan M Jankovic; Dragan R Milovanovic; Dragana Nedovic; Sladjana Petrovic
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009.

Authors:  Jindrich Srba; Veronika Descikova; Jiri Vlcek
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

6.  Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands.

Authors:  Ingrid Oosterhuis; Florence P A M van Hunsel; Eugène P van Puijenbroek
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

7.  Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.

Authors:  Paul Gavaza; Carolyn M Brown; Star Khoza
Journal:  Pharm World Sci       Date:  2010-07-23

8.  Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.

Authors:  Mark Greener
Journal:  EMBO Rep       Date:  2005-03       Impact factor: 8.807

9.  Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital.

Authors:  A Vallano; G Cereza; C Pedròs; A Agustí; I Danés; C Aguilera; J M Arnau
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

10.  Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).

Authors:  Frantz Thiessard; Emmanuel Roux; Ghada Miremont-Salamé; Annie Fourrier-Réglat; Françoise Haramburu; Pascale Tubert-Bitter; Bernard Bégaud
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.